Trials / Completed
CompletedNCT00961441
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- UCB BIOSCIENCES, Inc. · Industry
- Sex
- All
- Age
- 12 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Keppra XR | Keppra XR 500 mg tablets and Keppra XR 750 mg tablets Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2009-08-19
- Last updated
- 2015-08-06
- Results posted
- 2011-05-25
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00961441. Inclusion in this directory is not an endorsement.